CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReNerve Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReNerve Ltd
157 Heidelberg Road, Northcote
VIC  3070  Australia Ticker: RNVRNV
Business Summary
ReNerve Limited is an Australia-based medical device company developing tissue-based products for peripheral nerve repair and replacement and other related soft tissue surgical procedures. It is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. Its products include NervAlign Nerve Cuff, NervAlign Nerve Graft and NervAlign Bionic Nerve. NervAlign Nerve Cuff is a soft, compatible protective wrap used to protect repaired injured nerves. The product is being developed for the surgical repair of transected (cut) and damaged nerves. NervAlign nerve grafts offers surgeons the ability to repair damaged nerves (neurotmesis) without the need to harvest the sural nerve from the patient. It is developing, NervAlign Bionic Nerve, a combination polymer technology and its nerve graft to produce a replacement nerve that contains shaped ionic polymers which would enable the stimulation of the distal end of a nerve injury.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024-----

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Reginald S.Cooper 9/16/2016 9/16/2016
Chief Executive Officer, Executive Director Julian J.Chick 9/16/2016 9/16/2016
Chief Financial Officer, Company Secretary DavidLilja
Chief Scientific Officer, Executive Director David I.Rhodes 9/16/2016 9/16/2016
Independent Non-Executive Director MichaelPanaccio 4/27/2018 4/27/2018

General Information
Outstanding Shares: 141,837,806 (As of 6/30/2024)
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024